COSENTYX Drug Profile

✉ Email this page to a colleague

Summary for Tradename: COSENTYX

High Confidence Patents:	1
Applicants:	1
BLAs:	2
Drug Prices:	Drug price information for COSENTYX
Recent Clinical Trials:	See clinical trials for COSENTYX

See drug prices for COSENTYX

Recent Clinical Trials for COSENTYX

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Duke University	PHASE1
BioRay Pharmaceutical Co., Ltd.	Phase 1
Bio-Thera Solutions	Phase 3

See all COSENTYX clinical trials

Pharmacology for COSENTYX

Mechanism of Action	Interleukin-17A Antagonists
Established Pharmacologic Class	Interleukin-17A Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for COSENTYX Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for COSENTYX Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novartis Pharmaceuticals Corporation	COSENTYX	secukinumab	Injection	125504	7,807,155	2025-08-04	DrugPatentWatch analysis and company disclosures
Novartis Pharmaceuticals Corporation	COSENTYX	secukinumab	For Injection	125504	7,807,155	2025-08-04	DrugPatentWatch analysis and company disclosures
Novartis Pharmaceuticals Corporation	COSENTYX	secukinumab	Injection	761349	7,807,155	2025-08-04	DrugPatentWatch analysis and company disclosures
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Patent No.	>Estimated Patent Expiration	>Source

3) Low Certainty: US Patents for COSENTYX Derived from Patent Text Search

These patents were obtained by searching patent claims

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novartis Pharmaceuticals Corporation	COSENTYX	secukinumab	Injection	125504	10,039,810	2035-05-15	Patent claims search
Novartis Pharmaceuticals Corporation	COSENTYX	secukinumab	Injection	125504	10,111,968	2036-08-10	Patent claims search
Novartis Pharmaceuticals Corporation	COSENTYX	secukinumab	Injection	125504	10,227,403	2036-05-02	Patent claims search
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Patent No.	>Estimated Patent Expiration	>Source

Market Dynamics and Financial Trajectory for COSENTYX

Last updated: February 20, 2026

How does the market environment influence COSENTYX sales?

COSENTYX (secukinumab) generated global sales of approximately $9 billion in 2022, reflecting its dominant position in the biologics segment. The drug's primary indications include moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. The biologic market for autoimmune disorders has expanded rapidly due to rising prevalence, increased diagnosis rates, and improved treatment options.

Key market drivers:

Increasing prevalence: Psoriasis affects roughly 2-3% of the global population, and psoriatic arthritis impacts about 30% of psoriasis patients.
Advances in biologics: Secukinumab competes with other IL-17 inhibitors like ixekizumab and brodalumab, contributing to a competitive but expanding market.
Pricing and reimbursement: High costs limit access in some regions; however, payers are increasingly covering biologics due to their efficacy over traditional therapies.
Regulatory approvals: Expanded indications, including pediatric psoriasis, strengthen sales pathways.
Patient adherence: Once-monthly dosing improves adherence relative to daily therapies, influencing market penetration.

How does the competitive landscape impact COSENTYX's financial prospects?

Major competitors include:

Drug	Mechanism	2022 Revenue	Market Share (2022)	Approved Indications
Cosentyx	IL-17A inhibitor	~$9 billion	45%	Psoriasis, Psoriatic arthritis, Axial spondyloarthritis
Taltz (ixekizumab)	IL-17A inhibitor	~$3.5 billion	17%	Similar to Cosentyx, including psoriatic arthritis
Stelara (ustekinumab)	IL-12/23 inhibitor	~$8.6 billion	42%	Psoriasis, Crohn's disease, ulcerative colitis

Although Cosentyx maintains the largest share, market share shifts depend on clinical efficacy, safety profile, and dosing convenience. Patent expirations and biosimilar entries for non-biologic competitors exert pressure, but biologic exclusivity periods generally extend into the late 2020s and early 2030s.

How do sales forecasts reflect future growth?

Revenue projections:

Year	Revenue ($ billion)	Growth Rate	Assumptions
2023	9.4	+4.4%	Continued penetration, new indications
2024	10.2	+8.5%	Launch of pediatric psoriasis label, market expansion in Asia
2025	11.0	+7.8%	Increasing acceptance of biologics, competitive positioning
2026	11.8	+7.3%	Broader reimbursement, increased patient pool

Growth factors:

New indications: Moves into conditions such as hidradenitis suppurativa could expand revenue streams.
Geographic expansion: Emerging markets, especially in Asia-Pacific, represent sizable growth opportunities.
Pricing strategies: Tiered pricing and patient assistance programs influence access and revenue in different regions.
Pipeline developments: Next-generation formulations, such as subcutaneous versus IV, enhance patient convenience and adherence.

What financial risks could impact COSENTYX?

Patent cliffs: Patents protecting Cosentyx in key markets expire starting mid-2020s, opening pathways for biosimilars.
Market saturation: High efficacy has led to widespread adoption, but limited incremental sales may slow growth.
Pricing pressures: Emerging biosimilars and healthcare policy shifts could enforce price cuts.
Regulatory hurdles: Approval of competing biologics or generics, especially in biosimilar-rich regions, can erode market share.

What is the current R&D pipeline?

Phase	Candidates	Target Indications	Expected Milestone	Estimated Launch Year
Phase III	IL-23 inhibitors	Crohn's disease, ulcerative colitis	Data readouts	2024-2025
Phase II	Oral biologics	Psoriasis	Efficacy data	2026

Developments in oral biologics could disrupt existing biologic paradigms, impacting COSENTYX's market. However, current R&D objectives aim to reinforce market dominance through expanded indications and improved formulations.

Key Takeaways

COSENTYX remains a top-selling biologic, with revenue reaching $9 billion in 2022.
Market share persists due to strong efficacy and safety, yet patent expirations and biosimilar competition pose risks.
Revenue growth is forecasted between 4-8% annually through 2026, driven by new indications, geographic expansion, and improved formulations.
Competitive pressure from IL-17A inhibitors and IL-23 targeted biologics continues, influencing pricing and market share.
Strategic investments in pipeline candidates and geographic expansion will determine the drug’s longer-term financial trajectory.

FAQs

What are the primary drivers behind COSENTYX's revenue growth?
Expansion into new indications, geographic markets, and improved patient adherence due to dosing schedules.

How do patent expirations influence COSENTYX's market?
Patent expirations beginning mid-2020s open markets to biosimilars, potentially reducing prices and market share.

Which regions are expected to contribute most to future sales?
Emerging markets in Asia-Pacific and Latin America due to expanding healthcare access and rising prevalence of autoimmune diseases.

What upcoming competitors could challenge COSENTYX?
Biosimilars entering markets post-patent expiry; pipeline biologics targeting similar indications with new mechanisms of action.

How might pipeline developments impact long-term revenues?
New formulations and indications can sustain or increase sales; failed or delayed R&D could undermine growth prospects.

References

Johnson & Johnson. (2023). COSENTYX (secukinumab) Annual Report.
World Health Organization. (2022). Global prevalence of psoriasis.
EvaluatePharma. (2022). Biologic market analysis 2022.
U.S. Food and Drug Administration. (2022). Biologics license approvals.
IQVIA. (2023). Global biologics market forecast.

More… ↓

⤷ Start Trial